This biopharmaceutical company develops peptide-based pan-amyloid targeting agents to diagnose and treat all forms and stages of systemic amyloidosis, including subtypes with no current treatment options. Their immunotherapies and imaging diagnostic platform are designed to clear amyloid fibrils in patients with systemic amyloid diseases, such as AL, ATTR, and ALECT2 amyloidosis, providing an efficient treatment option for amyloidosis patients.